Anton C. Bizzell, M.D.
Chief Executive Officer
Anton C. Bizzell, M.D., President and CEO of The Bizzell Group, has more than 20 years of combined clinical, research, health services, policy and management experiences with various private and public organizations and agencies within HHS, including SAMHSA and NIH. Most of his career has been spent on public health issues related to access and quality of medical, substance abuse and behavioral health services. He has extensive experience in collaborating and interacting with health professional and community organizations as well as expert knowledge in identifying and treating medical diseases in the fields of primary care, mental health and substance abuse.
As a former medical officer in the CSAT’s Division of Pharmacologic, Dr. Bizzell led efforts in the area of prescription drug use, misuse and abuse for the agency, which includes collaborating with other federal agencies such as NIH, the Food and Drug Administration, the Drug Enforcement Administration, the White House Office of National Drug Control Policy and other federal, national, state and professional organizations. In addition, he provided medical and clinical advice for the 1550 methadone treatment programs in the United States, as well as oversaw national regulatory and educational efforts on buprenorphine, a medication-assisted treatment for treating individuals dependent on heroin and prescription drugs containing opiates. Other accomplishments include serving on the Advisory Board for the Federation of State Medical Board’s book entitled Responsible Opioid Prescribing: A Physician’s Guide and co-authoring “Ethical Issues in Addiction Practice,” a chapter in the Principles of Addiction Medicine, with CSAT Director Dr. Clark. Dr. Bizzell also wrote A Federal Perspective on the Abuse of Prescription Stimulants for Pediatric Annals and an article for Psychiatric Annals… continue reading.